Camibirstat Drug Asset Due Diligence Report 2026

This Camibirstat Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: HOLD / OPTION

Decision memo

Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.

The central underwriting question is whether Camibirstat can convert its Small molecule drug profile and SMARCA2 x SMARCA4 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Camibirstat (query alias: Camibirstat)
Modality / target	Small molecule drug; SMARCA2 x SMARCA4; SMARCA2 inhibitors, SMARCA4 inhibitors
Highest global status	Phase 2
Originator	Foghorn Therapeutics, Inc.
Active developers	UT MD Anderson Cancer Center, Foghorn Therapeutics, Inc.

The MCP disease footprint includes Extensive stage Small Cell Lung Cancer, Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07551635	Phase 2	Not yet recruiting	20	Primary endpoint not disclosed in English source
NCT07283094	Phase 1	Recruiting	33	Primary endpoint not disclosed in English source
NCT04891757	Phase 1	Active, not recruiting	144	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Evidence gap

The Clinical Trials MCP returned no matched public result record. This is a gating diligence gap, not evidence of failure.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Camibirstat addresses Extensive stage Small Cell Lung Cancer, Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 2 matched transaction record(s) under the scope “target-level comparable: SMARCA2 x SMARCA4.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: SMARCA2 x SMARCA4 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2023-11-01	Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology	Discovery	Financial terms not disclosed
2021-12-13	Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform	Preclinical	US$300.0M upfront; US$1,300.0M milestones

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Patent source description not available in English”. The milestone feed surfaced a patent-application signal described as “Method for inducing generation of peripheral CD4CD8 double positive T cells and application thereof”. The milestone feed surfaced a patent-application signal described as “Combination therapy for treating hematological cancers”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

HOLD / OPTION